XK
TGTX icon

Xact Kapitalforvaltning’s TG Therapeutics TGTX Stock Holding History

Xact Kapitalforvaltning’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,700
Closed -$60K – 1541
2018
Q4 		$60K Hold
14,700
– – ﹤0.01% 1490
2018
Q3 		$82K Buy
14,700
+4,100
+39% +$46.8K ﹤0.01% 1550
2018
Q2 		$139K Buy
+10,600
New +$146K ﹤0.01% 1572

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Xact Kapitalforvaltning's TGTX Position: Q1 2019 in Review

Xact Kapitalforvaltning sold out of TG Therapeutics (TGTX) in Q1 2019, closing a stake of 14,700 shares — an estimated $60K sold.

Xact Kapitalforvaltning first reported a position in TGTX in Q2 2018 and held it in 3 quarters. The position peaked at $139K in Q2 2018. 113 funds tracked by Wall St. Rank hold TGTX as of Q1 2019.

  • Xact Kapitalforvaltning reported no remaining TG Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 14,700 TG Therapeutics shares in Q1 2019, an estimated $60K.
  • Xact Kapitalforvaltning first reported a position in TG Therapeutics in Q2 2018 and held it in 3 quarters.
  • Xact Kapitalforvaltning's TG Therapeutics position peaked at $139K in Q2 2018.
  • 113 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2019, filed 10 May 2019.